Trial Profile
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Portal hypertension; Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Actelion Pharmaceuticals
- 09 Mar 2020 Results of post hoc exploratory analyses conducted on full set analysis (all randomized participants) for double-blind treatment period assessing implications of hemodynamics changes in patients with post pulmonary hypertension published in the Liver Transplantation
- 19 Dec 2018 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 Results assessing efficacy and safety presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.